Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Q32 Bio Inc. (QTTB)

Q32 Bio appoints José Trevejo as chief medical officer, Ellie Hershberger as CDO

Neutral Impact 3 of 5 leadership Written later

Q32 Bio named José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer on September 14, 2026. The company said the appointments come as it moves into a late clinical stage and prepares a registration-directed program for bempikibart in alopecia areata.

Key points

  • Trevejo was CMO at Enveda Therapeutics from July 2024 to September 2026 and earlier CMO at Tarsus Pharmaceuticals from February 2022 to February 2024.
  • Hershberger was Chief Development Officer at Adagio Therapeutics, now Invivyd, from June 2020 to January 2023.
  • Company plans to advance bempikibart into a registration-directed program in alopecia areata in the first half of 2027.

The filing

CompanyQ32 Bio Inc. (QTTB)
Form8-K, current report
Filed with the SECSep 14, 2026, 7:15 AM ET
Accession number0001193125-26-389836

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.